Antares Pharma, Inc. (ATRS)

[Jon20ABX]

Bio,

The board would be the first line of defense, yes. They would have to approve an offer then present it to the shareholders. The point is a buyout offer (be it high or low) doesn't automatically result in a "buyout", which is what jb seemed to be inferring or at least inquiring. Any offer can be rejected by the board, the shareholders or both.

Antares, for now, remains a pipeline play. I strongly believe that EpiPen, along with Otrexup and whatever other new Antares/Teva drug combos will bring Antares to sustainable profitability in mid-2015 (at the latest). As you said, the company has NEVER given earnings projections, ever, about anything. Esoteric comments like "we believe this will be a significant opportunity" (Pfizer drug), or the potential market opportunity for certain drugs has been given like Otrexup, but never earnings estimates or when the company will hit profitability. PW said guidance for Otrexup would be given in August of this year. We'll see if that still remains the case on August earnings call.

It will be interesting to see what the QST pharma partner will pay Antares to market that drug. I still believe that Antares will be "in play" once the QST trail results show "all systems go".